Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Integrins and cardiovascular disease

K J Clemetson1, J M Clemetson

  • 1Theodor Kocher Institute, University of Berne, Switzerland. clemetson@tki.unibe.ch

Cellular and Molecular Life Sciences : CMLS
|July 24, 1998
PubMed
Summary

Targeting alpha IIb beta 3 integrins is crucial for managing cardiovascular diseases. Inhibiting this platelet receptor reduces disease incidence and mortality, improving patient care and stimulating further research.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Distinct effects of Re- and S-forms of LPS on modulating platelet activation.

Journal of thrombosis and haemostasis : JTH·2013
Same author

Potential therapeutic targeting of platelet-mediated cellular interactions in atherosclerosis and inflammation.

Current medicinal chemistry·2011
Same author

The role of platelets in defence against pathogens.

Hamostaseologie·2011
Same author

Classification and nomenclature of snake venom C-type lectins and related proteins.

Toxicon : official journal of the International Society on Toxinology·2009
Same author

Scientific and standardization committee communications: classification and nomenclature of snake venom C-type lectins and related proteins.

Journal of thrombosis and haemostasis : JTH·2008
Same author

Snake venom C-type lectins as tools in platelet research.

Platelets·2006

Area of Science:

  • Cardiovascular Biology
  • Integrin Signaling
  • Thrombosis Research

Background:

  • Cardiovascular diseases stem from abnormal cell interactions, leading to atherosclerosis and thrombus formation.
  • Platelet activation and embolus formation are critical events in cardiovascular disease progression.
  • Integrins, particularly platelet alpha IIb beta 3, play a significant role in these pathological processes.

Purpose of the Study:

  • To highlight the importance of alpha IIb beta 3 integrin as a therapeutic target in cardiovascular diseases.
  • To discuss the development and impact of alpha IIb beta 3 inhibitors on patient outcomes.
  • To explore ongoing research into integrin function and novel inhibitor development for cardiovascular conditions.

Main Methods:

  • Review of evidence supporting the role of alpha IIb beta 3 in cardiovascular disease.
  • Analysis of the therapeutic strategy involving alpha IIb beta 3 inhibition.
  • Examination of research advancements, including specific inhibitors and gene-ablated mouse models.

Main Results:

  • Regulated inhibition of alpha IIb beta 3 integrin leads to reduced cardiovascular disease incidence and mortality.
  • Alpha IIb beta 3 inhibitors have demonstrated improvements in patient care.
  • Research has expanded to investigate integrins on other vascular cells and develop new inhibitors.

Conclusions:

  • Alpha IIb beta 3 integrin is a validated and important therapeutic target for cardiovascular diseases.
  • The development of alpha IIb beta 3 inhibitors represents a significant advancement in managing acute and chronic cardiovascular conditions.
  • Continued research on integrins is vital for understanding cardiovascular system development and discovering novel therapeutic strategies.

Related Experiment Videos